Biohaven Ltd. (NYSE:BHVN – Get Free Report) CEO Vlad Coric acquired 121,951 shares of Biohaven stock in a transaction on Monday, April 22nd. The stock was purchased at an average price of $41.00 per share, with a total value of $4,999,991.00. Following the transaction, the chief executive officer now directly owns 1,788,417 shares in the company, valued at approximately $73,325,097. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Biohaven Price Performance
BHVN stock opened at $38.70 on Thursday. The business has a fifty day moving average price of $51.49 and a 200 day moving average price of $41.81. Biohaven Ltd. has a fifty-two week low of $12.35 and a fifty-two week high of $62.21. The stock has a market capitalization of $3.17 billion, a price-to-earnings ratio of -6.84 and a beta of 1.18.
Biohaven (NYSE:BHVN – Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). On average, equities analysts expect that Biohaven Ltd. will post -5.85 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Research Report on Biohaven
Institutional Investors Weigh In On Biohaven
Hedge funds and other institutional investors have recently made changes to their positions in the company. Thompson Davis & CO. Inc. acquired a new stake in shares of Biohaven in the 4th quarter valued at $214,000. Prevail Innovative Wealth Advisors LLC acquired a new stake in shares of Biohaven in the 4th quarter valued at $230,000. Private Advisor Group LLC acquired a new stake in shares of Biohaven in the 4th quarter valued at $231,000. Capstone Investment Advisors LLC acquired a new stake in shares of Biohaven in the 4th quarter valued at $235,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Biohaven in the 3rd quarter valued at $236,000. 88.78% of the stock is owned by institutional investors and hedge funds.
About Biohaven
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Featured Articles
- Five stocks we like better than Biohaven
- The “How” and “Why” of Investing in 5G Stocks
- High-Yield Texas Instruments Could Hit New Highs Soon
- How is Compound Interest Calculated?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What Makes a Stock a Good Dividend Stock?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.